Evidence map›Paper›PMID 42055552›Full record

ArticleNucleic acids research2026

The interferon-stimulated gene product HERC5 inhibits human LINE-1 retrotransposition with an ISGylation-independent mechanism.

Kei Nishimori, Ahmad Luqman-Fatah, Yuzo Watanabe, Mari Takahashi, Takuhiro Ito, Fuyuki Ishikawa, Tomoichiro Miyoshi

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kei NishimoriLaboratory for Retrotransposon Dynamics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.ORCID 0009-0008-2269-5452
Ahmad Luqman-FatahLaboratory for Retrotransposon Dynamics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Yuzo WatanabeProteomics Facility, Graduate School of Biostudies, Kyoto University, Kyoto 606-8502, Japan.
Mari TakahashiLaboratory for Translation Structural Biology, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Takuhiro ItoLaboratory for Translation Structural Biology, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.ORCID 0000-0003-3704-5205
Fuyuki IshikawaDepartment of Gene Mechanisms, Graduate School of Biostudies, Kyoto University, Kyoto 606-8501, Japan.
Tomoichiro MiyoshiLaboratory for Retrotransposon Dynamics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.ORCID 0000-0002-5319-7877

Funding

AMED JP24gm1410001Astellas Foundation for Research on Metabolic DisordersJSPS KAKENHI 21K19219JSPS KAKENHI 23K23863JSPS KAKENHI JP19H05655JSPS KAKENHI JP21H05281JST PRESTO JPMJPR2289Nagase Science Technology FoundationRIKEN Junior Research AssociateRIKEN Special Postdoctoral Research programsTakeda Science Foundation
6 · The paper itself

Abstract

Mobilization of Long INterspersed Element-1 (LINE-1 or L1) compromises genome stability and can cause sporadic genetic diseases. Accordingly, cells have evolved multiple mechanisms to restrict L1 retrotransposition. Several interferon-stimulated genes (ISGs) that interact with cytoplasmic L1 ribonucleoproteins (RNPs), which contain the L1-encoded proteins ORF1p and ORF2p, have been identified as suppressors of L1 retrotransposition. We previously reported that the ISG protein HECT and RLD domain containing E3 ubiquitin-protein ligase 5 (HERC5) efficiently inhibits L1 retrotransposition. While HERC5 is known to restrict numerous viruses through ISGylation, how HERC5 inhibits L1 remains to be elucidated. Here, we show that HERC5 inhibits L1 retrotransposition through an ISGylation-independent mechanism. HERC5 interacts with L1 RNA and selectively reduces ORF1p levels in a manner that requires the full-length ORF1p expression. We further demonstrate that HERC5 decreases L1 translation efficiency and alters L1 RNP composition. Our comparative analysis further suggests that HERC5 may have acquired its L1-inhibitory function during the evolution of the small HERC family. These findings uncover a previously unidentified mechanism by which an ISG protein associates with and inhibits L1 and suggest a role for HERC5 as an evolutionarily adapted restriction factor that expands the repertoire of cellular defenses against retrotransposons.

Indexed as

Long Interspersed Nucleotide ElementsUbiquitin-Protein LigasesHEK293 CellsHeLa CellsHumansIntracellular Signaling Peptides and ProteinsProteinsRibonucleoproteinsHERC5 protein, humanIntracellular Signaling Peptides and ProteinsORF1 protein, humanProteinsRibonucleoproteinsUbiquitin-Protein Ligases

Identifiers

PMID42055552
PMCPMC13128273

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.